Norclostebol

Norclostebol (INN), also known as 4-chlorotestosterone acetate (USAN) or as 4-chloroandrost-4-en-17β-ol-3-one 17β-acetate, is a synthetic, injected anabolic–androgenic steroid (AAS) and a derivative of testosterone that was marketed in the United States from the late 1950s until the early 1960s. It is the 4-chloro-substituted analogue of testosterone and the parent compound of chlorodehydromethyltestosterone.

Chemistry

Norclostebol, also known as 4-chlorotestosterone 17β-acetate or as 4-chloroandrost-4-en-17β-ol-3-one 17β-acetate, is a synthetic androstane steroid and a derivative of testosterone. It is more specifically a derivative of clostebol (4-chlorotestosterone), and is the parent compound of chlorodehydromethyltestosterone.

History

Norclostebol was first described in 1956 and was introduced for medical use in the United States in the late 1950s. It was marketed by the pharmaceutical company Squibb under the brand name Nilevar. The drug was also marketed in France under the brand name Clinibolin. Norclostebol was withdrawn in the United States in the early 1960s and appears to no longer be marketed.

Society and culture

Generic names

Norclostebol is the International Nonproprietary Name (INN) and British Approved Name (BAN) of the drug while 4-chlorotestosterone acetate is its United States Adopted Name (USAN).

Brand names

Norclostebol has been marketed under a variety of brand names including Nilevar and Clinibolin among others.

See also

• List of androgens/anabolic steroids

Norclostebol Resources
Latest articles Most recent articles Ongoing trials	Wikipedia